MARKET

CRNX

CRNX

Crinetics Pharmaceuticals
NASDAQ
36.77
-1.54
-4.02%
After Hours: 36.77 0 0.00% 16:10 05/15 EDT
OPEN
38.02
PREV CLOSE
38.31
HIGH
38.06
LOW
36.40
VOLUME
1.11M
TURNOVER
--
52 WEEK HIGH
57.99
52 WEEK LOW
25.83
MARKET CAP
3.88B
P/E (TTM)
-7.1633
1D
5D
1M
3M
1Y
5Y
1D
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Q1 2026 Revenue Growth And Wider Net Loss
Simply Wall St · 15h ago
3 Best Healthcare Stocks to Buy in May 2026, According to Analysts
TipRanks · 1d ago
Crinetics Pharmaceuticals Price Target Cut to $88.00/Share From $89.00 by Evercore ISI Group
Dow Jones · 1d ago
Crinetics Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
Dow Jones · 1d ago
Evercore ISI Group Maintains Outperform on Crinetics Pharmaceuticals, Lowers Price Target to $88
Benzinga · 1d ago
Industry Analysts Just Upgraded Their Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Revenue Forecasts By 11%
Simply Wall St · 3d ago
Crinetics price target lowered to $84 from $87 at Oppenheimer
TipRanks · 5d ago
Twilio To Rally Over 25%? Here Are 10 Top Analyst Forecasts For Monday
Benzinga · 5d ago
More
About CRNX
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.

Webull offers Crinetics Pharmaceuticals Inc stock information, including NASDAQ: CRNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRNX stock methods without spending real money on the virtual paper trading platform.